

From: Cohn, Amanda (CDC/DDID/NCIRD/OD) [anc0@cdc.gov]
Sent: 5/13/2021 4:19:57 PM
To: Marks, Peter [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dfbb2b5bd38445cb9c9adca3f72df53a-MarksP]; Schuchat, Anne (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=848b7544f27d4a2a9554a80e78d002fc-HHS-ac1-cd]
CC: Gruber, Marion [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=019cd2669c7048f7a116d72b7682de44-gruber]; Walinsky, Sarah [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=97a2ad6b3c4549a78542fce1a086f7ea-Sarah.Walin]
Subject: RE: [EXTERNAL] RE: Quick Q - vaccine coadministration

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Sure, we are happy to. I am available late afternoon/early evening but am giving a talk from 7:30-9.

I have another issue to discuss as well, reports of myocarditis in adolescents. I am putting together an email, but this may come to the surface this weekend.

Thanks,
Amanda

From: Marks, Peter <Peter.Marks@fda.hhs.gov>
Sent: Thursday, May 13, 2021 4:16 PM
To: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Cohn, Amanda (CDC/DDID/NCIRD/OD) <anc0@cdc.gov>
Cc: Gruber, Marion (FDA/CBER) <Marion.Gruber@fda.hhs.gov>; Walinsky, Sarah (FDA/CDER) <Sarah.Walinsky@fda.hhs.gov>
Subject: FW: [EXTERNAL] RE: Quick Q - vaccine coadministration

Dear Anne and Amanda,

Could we have a discussion here? We could have missed something at ACIP, but we have the following concerns:

- 1) We would recommend consideration be given to stating that the coadministration of live attenuated virus vaccines with COVID-19 vaccines should be avoided, if possible.
- 2) At the very least, there should be some mention that coadministration could possibly reduce the efficacy of either or both of the co-administered vaccines.

Thanks. If you think we are totally off base, just tell us so.

Best Regards,
Peter

From: McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>
Sent: Thursday, May 13, 2021 4:00 PM
To: Marks, Peter <Peter.Marks@fda.hhs.gov>
Subject: FW: [EXTERNAL] RE: Quick Q - vaccine coadministration

Hi Peter –

Here's the latest version.

Lorrie

From: Woodworth, Kate (CDC/DDNID/NCBDDD/DBDID) <vnt0@cdc.gov>
Sent: Thursday, May 13, 2021 3:54 PM
To: Nordlund, Kristen (CDC) <hok4@cdc.gov>; McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>; Coffin, Nicole (CDC) <ndc3@cdc.gov>
Cc: Mbaeyi, Sarah A (CDC) <vif6@cdc.gov>
Subject: [EXTERNAL] RE: Quick Q - vaccine coadministration

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Here is the latest version if helpful!

Coadministration with other vaccines

COVID-19 vaccines were previously recommended to be administered alone, with a minimum interval of 14 days before or after administration of any other vaccines. This was out of an abundance of caution and not due to any known safety or immunogenicity concerns. However, substantial data have now been collected regarding the safety of COVID-19 vaccines currently authorized by FDA for use under EUA. Although data are not available for COVID-19 vaccines administered simultaneously with other vaccines, extensive experience with non-COVID-19 vaccines has demonstrated that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously as when they are administered alone.

COVID-19 vaccines and other vaccines **may now be administered without regard to timing**. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines. When deciding whether to coadminister with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.

If multiple vaccines are administered at a single visit, administer each injection in a different injection site. For adolescents and adults, the deltoid muscle can be used for more than one intramuscular injection.

Best practices for multiple injections include:

- Label each syringe with name and dosage (amount) of the vaccine, lot number, the initials of the preparer, and the exact beyond-use time, if applicable.
- Separate injection sites by 1 inch or more, if possible.
- **Administer COVID-19 and vaccines that may be more likely to cause a local reaction (e.g., tetanus-toxoid-containing and adjuvanted vaccines) in different limbs, if possible.**

From: Nordlund, Kristen (CDC/DDID/NCIRD/OD) <hok4@cdc.gov>
Sent: Thursday, May 13, 2021 3:49 PM
To: McNeill, Lorrie (FDA/CBER) <Lorrie.McNeill@fda.hhs.gov>; Coffin, Nicole (CDC/DDID/NCEZID/DHQP) <ndc3@cdc.gov>
Cc: Woodworth, Kate (CDC/DDNID/NCBDDD/DBDID) <vnt0@cdc.gov>; Mbaeyi, Sarah (CDC/DDID/NCIRD/OD) <vif6@cdc.gov>
Subject: RE: Quick Q - vaccine coadministration

Hi Lorrie,

We plan to updated the clinical guidance tomorrow after 1pm. Attached is the edited version of the guidance that we put up during ACIP, but I've not seen the exact language. I've cced Drs. Woodworth and Mbaeyi who are working on this in case they can share the latest version.

Thanks,
Kristen

From: McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>

Sent: Thursday, May 13, 2021 3:43 PM

To: Nordlund, Kristen (CDC/DDID/NCIRD/OD) <hok4@cdc.gov>; Coffin, Nicole (CDC/DDID/NCEZID/DHQP) <ndc3@cdc.gov>

Subject: Quick Q - vaccine coadministration

Hi all – Dr. Marks and Dr. Woodcock participated in a stakeholder call this afternoon to discuss the authorization of the Pfizer vaccine for 12 through 15 year olds, and a question was asked about coadministration of COVID vaccine with other vaccines (meaning childhood vaccines). One of the participants said CDC was recommending that there no longer needed to be a waiting period between vaccination with COVID and other vaccines. I'm not sure he/she was completely correct. We know the issue was discussed at ACIP yesterday (I was unable to watch), but am not sure any recommendations have come out yet. Can you all let me know if there's an update?

Thanks much!

Lorrie

Lorrie H. McNeill

Director

Office of Communication, Outreach and Development

Center for Biologics Evaluation and Research

U.S. Food and Drug Administration

Tel: 240-402-8119

lorrie.mcneill@fda.hhs.gov



From: Schuchat, Anne MD (CDC/OD) [acs1@cdc.gov]
Sent: 5/13/2021 4:23:53 PM
To: Cohn, Amanda C (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d4cbff30d34c4611a2e973fcb192de37-HHS-anc0-cd]; Marks, Peter [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=dfbb2b5bd38445cb9c9adca3f72df53a-MarksP]
CC: Gruber, Marion [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=019cd2669c7048f7a116d72b7682de44-gruber]; Walinsky, Sarah [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=97a2ad6b3c4549a78542fce1a086f7ea-Sarah.Walin]
Subject: RE: [EXTERNAL] RE: Quick Q - vaccine coadministration

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Great if you can do the call w/out me. Am happy to have our folks reconsider additional clinical considerations.

From: Cohn, Amanda (CDC/DDID/NCIRD/OD) <anc0@cdc.gov>
Sent: Thursday, May 13, 2021 4:20 PM
To: Marks, Peter (FDA/CBER) <Peter.Marks@fda.hhs.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Cc: Gruber, Marion (FDA/CBER) <Marion.Gruber@fda.hhs.gov>; Walinsky, Sarah (FDA/CDER) <Sarah.Walinsky@fda.hhs.gov>
Subject: RE: [EXTERNAL] RE: Quick Q - vaccine coadministration

Sure, we are happy to. I am available late afternoon/early evening but am giving a talk from 7:30-9.

I have another issue to discuss as well, reports of myocarditis in adolescents. I am putting together an email, but this may come to the surface this weekend.

Thanks,
Amanda

From: Marks, Peter <Peter.Marks@fda.hhs.gov>
Sent: Thursday, May 13, 2021 4:16 PM
To: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Cohn, Amanda (CDC/DDID/NCIRD/OD) <anc0@cdc.gov>
Cc: Gruber, Marion (FDA/CBER) <Marion.Gruber@fda.hhs.gov>; Walinsky, Sarah (FDA/CDER) <Sarah.Walinsky@fda.hhs.gov>
Subject: FW: [EXTERNAL] RE: Quick Q - vaccine coadministration

Dear Anne and Amanda,

Could we have a discussion here? We could have missed something at ACIP, but we have the following concerns:

- 1) We would recommend consideration be given to stating that the coadministration of live attenuated virus vaccines with COVID-19 vaccines should be avoided, if possible.
- 2) At the very least, there should be some mention that coadministration could possibly reduce the efficacy of either or both of the co-administered vaccines.

Thanks. If you think we are totally off base, just tell us so.

Best Regards,

Peter

From: McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>
Sent: Thursday, May 13, 2021 4:00 PM
To: Marks, Peter <Peter.Marks@fda.hhs.gov>
Subject: FW: [EXTERNAL] RE: Quick Q - vaccine coadministration

Hi Peter –

Here's the latest version.

Lorrie

From: Woodworth, Kate (CDC/DDNID/NCBDDD/DBDID) <vnt0@cdc.gov>
Sent: Thursday, May 13, 2021 3:54 PM
To: Nordlund, Kristen (CDC) <hok4@cdc.gov>; McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>; Coffin, Nicole (CDC) <ndc3@cdc.gov>
Cc: Mbaeyi, Sarah A (CDC) <vif6@cdc.gov>
Subject: [EXTERNAL] RE: Quick Q - vaccine coadministration

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Here is the latest version if helpful!

Coadministration with other vaccines

COVID-19 vaccines were previously recommended to be administered alone, with a minimum interval of 14 days before or after administration of any other vaccines. This was out of an abundance of caution and not due to any known safety or immunogenicity concerns. However, substantial data have now been collected regarding the safety of COVID-19 vaccines currently authorized by FDA for use under EUA. Although data are not available for COVID-19 vaccines administered simultaneously with other vaccines, extensive experience with non-COVID-19 vaccines has demonstrated that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously as when they are administered alone.

COVID-19 vaccines and other vaccines **may now be administered without regard to timing**. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines. When deciding whether to coadminister with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.

If multiple vaccines are administered at a single visit, administer each injection in a different injection site. For adolescents and adults, the deltoid muscle can be used for more than one intramuscular injection.

Best practices for multiple injections include:

- Label each syringe with name and dosage (amount) of the vaccine, lot number, the initials of the preparer, and the exact beyond-use time, if applicable.
- Separate injection sites by 1 inch or more, if possible.
- **Administer COVID-19 and vaccines that may be more likely to cause a local reaction (e.g., tetanus-toxoid-containing and adjuvanted vaccines) in different limbs, if possible.**

From: Nordlund, Kristen (CDC/DDID/NCIRD/OD) <hok4@cdc.gov>
Sent: Thursday, May 13, 2021 3:49 PM
To: McNeill, Lorrie (FDA/CBER) <Lorrie.McNeill@fda.hhs.gov>; Coffin, Nicole (CDC/DDID/NCEZID/DHQP) <ndc3@cdc.gov>
Cc: Woodworth, Kate (CDC/DDNID/NCBDDD/DBDID) <vnt0@cdc.gov>; Mbaeyi, Sarah (CDC/DDID/NCIRD/OD) <vif6@cdc.gov>
Subject: RE: Quick Q - vaccine coadministration

Hi Lorrie,

We plan to updated the [clinical guidance](#) tomorrow after 1pm. Attached is the edited version of the guidance that we put up during ACIP, but I've not seen the exact language. I've cced Drs. Woodworth and Mbaeyi who are working on this in case they can share the latest version.

Thanks,
Kristen

From: McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>
Sent: Thursday, May 13, 2021 3:43 PM
To: Nordlund, Kristen (CDC/DDID/NCIRD/OD) <hok4@cdc.gov>; Coffin, Nicole (CDC/DDID/NCEZID/DHQP) <ndc3@cdc.gov>
Subject: Quick Q - vaccine coadministration

Hi all – Dr. Marks and Dr. Woodcock participated in a stakeholder call this afternoon to discuss the authorization of the Pfizer vaccine for 12 through 15 year olds, and a question was asked about coadministration of COVID vaccine with other vaccines (meaning childhood vaccines). One of the participants said CDC was recommending that there no longer needed to be a waiting period between vaccination with COVID and other vaccines. I'm not sure he/she was completely correct. We know the issue was discussed at ACIP yesterday (I was unable to watch), but am not sure any recommendations have come out yet. Can you all let me know if there's an update?

Thanks much!

Lorrie

Lorrie H. McNeill
Director

Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
U.S. Food and Drug Administration
Tel: 240-402-8119
lorrie.mcneill@fda.hhs.gov



From: Marks, Peter [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DFBB2B5BD38445CB9C9ADCA3F72DF53A-MARKSP]
Sent: 5/13/2021 4:33:53 PM
To: Schuchat, Anne (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=848b7544f27d4a2a9554a80e78d002fc-HHS-acs1-cd]; Cohn, Amanda C (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d4cbff30d34c4611a2e973fcb192de37-HHS-anc0-cd]
CC: Gruber, Marion [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=019cd2669c7048f7a116d72b7682de44-gruber]; Walinsky, Sarah [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=97a2ad6b3c4549a78542fce1a086f7ea-Sarah.Walin]
Subject: RE: [EXTERNAL] RE: Quick Q - vaccine coadministration

Dear Anne,

Thanks so much. Will give Amanda a call.

Best Regards,
Peter

From: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Sent: Thursday, May 13, 2021 4:24 PM
To: Cohn, Amanda C (CDC) <anc0@cdc.gov>; Marks, Peter <Peter.Marks@fda.hhs.gov>
Cc: Gruber, Marion <Marion.Gruber@fda.hhs.gov>; Walinsky, Sarah <Sarah.Walinsky@fda.hhs.gov>
Subject: RE: [EXTERNAL] RE: Quick Q - vaccine coadministration

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Great if you can do the call w/out me. Am happy to have our folks reconsider additional clinical considerations.

From: Cohn, Amanda (CDC/DDID/NCIRD/OD) <anc0@cdc.gov>
Sent: Thursday, May 13, 2021 4:20 PM
To: Marks, Peter (FDA/CBER) <Peter.Marks@fda.hhs.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Cc: Gruber, Marion (FDA/CBER) <Marion.Gruber@fda.hhs.gov>; Walinsky, Sarah (FDA/CDER) <Sarah.Walinsky@fda.hhs.gov>
Subject: RE: [EXTERNAL] RE: Quick Q - vaccine coadministration

Sure, we are happy to. I am available late afternoon/early evening but am giving a talk from 7:30-9.

I have another issue to discuss as well, reports of myocarditis in adolescents. I am putting together an email, but this may come to the surface this weekend.

Thanks,
Amanda

From: Marks, Peter <Peter.Marks@fda.hhs.gov>
Sent: Thursday, May 13, 2021 4:16 PM
To: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Cohn, Amanda (CDC/DDID/NCIRD/OD) <anc0@cdc.gov>
Cc: Gruber, Marion (FDA/CBER) <Marion.Gruber@fda.hhs.gov>; Walinsky, Sarah (FDA/CDER)

<Sarah.Walinsky@fda.hhs.gov>

Subject: FW: [EXTERNAL] RE: Quick Q - vaccine coadministration

Dear Anne and Amanda,

Could we have a discussion here? We could have missed something at ACIP, but we have the following concerns:

- 1) We would recommend consideration be given to stating that the coadministration of live attenuated virus vaccines with COVID-19 vaccines should be avoided, if possible.
- 2) At the very least, there should be some mention that coadministration could possibly reduce the efficacy of either or both of the co-administered vaccines.

Thanks. If you think we are totally off base, just tell us so.

Best Regards,
Peter

From: McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>
Sent: Thursday, May 13, 2021 4:00 PM
To: Marks, Peter <Peter.Marks@fda.hhs.gov>
Subject: FW: [EXTERNAL] RE: Quick Q - vaccine coadministration

Hi Peter –

Here's the latest version.

Lorrie

From: Woodworth, Kate (CDC/DDNID/NCBDDD/DBDID) <vnt0@cdc.gov>
Sent: Thursday, May 13, 2021 3:54 PM
To: Nordlund, Kristen (CDC) <hok4@cdc.gov>; McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>; Coffin, Nicole (CDC) <ndc3@cdc.gov>
Cc: Mbaeyi, Sarah A (CDC) <vif6@cdc.gov>
Subject: [EXTERNAL] RE: Quick Q - vaccine coadministration

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Here is the latest version if helpful!

Coadministration with other vaccines

COVID-19 vaccines were previously recommended to be administered alone, with a minimum interval of 14 days before or after administration of any other vaccines. This was out of an abundance of caution and not due to any known safety or immunogenicity concerns. However, substantial data have now been collected regarding the safety of COVID-19 vaccines currently authorized by FDA for use under EUA. Although data are not available for COVID-19 vaccines administered simultaneously with other vaccines, extensive experience with non-COVID-19 vaccines has demonstrated that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously as when they are administered alone.

COVID-19 vaccines and other vaccines **may now be administered without regard to timing**. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration

within 14 days. It is unknown whether reactogenicity is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines. When deciding whether to coadminister with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.

If multiple vaccines are administered at a single visit, administer each injection in a different injection site. For adolescents and adults, the deltoid muscle can be used for more than one intramuscular injection.

Best practices for multiple injections include:

- Label each syringe with name and dosage (amount) of the vaccine, lot number, the initials of the preparer, and the exact beyond-use time, if applicable.
- Separate injection sites by 1 inch or more, if possible.
- **Administer COVID-19 and vaccines that may be more likely to cause a local reaction (e.g., tetanus-toxoid-containing and adjuvanted vaccines) in different limbs, if possible.**

From: Nordlund, Kristen (CDC/DDID/NCIRD/OD) <hok4@cdc.gov>

Sent: Thursday, May 13, 2021 3:49 PM

To: McNeill, Lorrie (FDA/CBER) <Lorrie.McNeill@fda.hhs.gov>; Coffin, Nicole (CDC/DDID/NCEZID/DHQP) <ndc3@cdc.gov>

Cc: Woodworth, Kate (CDC/DDNID/NCBDDD/DBDID) <vnt0@cdc.gov>; Mbaeyi, Sarah (CDC/DDID/NCIRD/OD) <vif6@cdc.gov>

Subject: RE: Quick Q - vaccine coadministration

Hi Lorrie,

We plan to update the clinical guidance tomorrow after 1pm. Attached is the edited version of the guidance that we put up during ACIP, but I've not seen the exact language. I've cced Drs. Woodworth and Mbaeyi who are working on this in case they can share the latest version.

Thanks,
Kristen

From: McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>

Sent: Thursday, May 13, 2021 3:43 PM

To: Nordlund, Kristen (CDC/DDID/NCIRD/OD) <hok4@cdc.gov>; Coffin, Nicole (CDC/DDID/NCEZID/DHQP) <ndc3@cdc.gov>

Subject: Quick Q - vaccine coadministration

Hi all – Dr. Marks and Dr. Woodcock participated in a stakeholder call this afternoon to discuss the authorization of the Pfizer vaccine for 12 through 15 year olds, and a question was asked about coadministration of COVID vaccine with other vaccines (meaning childhood vaccines). One of the participants said CDC was recommending that there no longer needed to be a waiting period between vaccination with COVID and other vaccines. I'm not sure he/she was completely correct. We know the issue was discussed at ACIP yesterday (I was unable to watch), but am not sure any recommendations have come out yet. Can you all let me know if there's an update?

Thanks much!

Lorrie

Lorrie H. McNeill
Director

Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
U.S. Food and Drug Administration
Tel: 240-402-8119
lorrie.mcneill@fda.hhs.gov



From: Marks, Peter [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=DFBB2B5BD38445CB9C9ADCA3F72DF53A-MARKSP]
Sent: 5/13/2021 4:36:22 PM
To: Cohn, Amanda C (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d4cbff30d34c4611a2e973fcb192de37-HHS-anc0-cd]; Schuchat, Anne (CDC) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=848b7544f27d4a2a9554a80e78d002fc-HHS-acs1-cd]
CC: Gruber, Marion [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=019cd2669c7048f7a116d72b7682de44-gruber]; Walinsky, Sarah [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=97a2ad6b3c4549a78542fce1a086f7ea-Sarah.Walin]
Subject: RE: [EXTERNAL] RE: Quick Q - vaccine coadministration

Dear Amanda,

Can I give you a call about 6 PM with Marion? If so, what number? Thanks.

Best Regards,
Peter

From: Cohn, Amanda (CDC/DDID/NCIRD/OD) <anc0@cdc.gov>
Sent: Thursday, May 13, 2021 4:20 PM
To: Marks, Peter <Peter.Marks@fda.hhs.gov>; Schuchat, Anne (CDC) <acs1@cdc.gov>
Cc: Gruber, Marion <Marion.Gruber@fda.hhs.gov>; Walinsky, Sarah <Sarah.Walinsky@fda.hhs.gov>
Subject: RE: [EXTERNAL] RE: Quick Q - vaccine coadministration

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Sure, we are happy to. I am available late afternoon/early evening but am giving a talk from 7:30-9.

I have another issue to discuss as well, reports of myocarditis in adolescents. I am putting together an email, but this may come to the surface this weekend.

Thanks,
Amanda

From: Marks, Peter <Peter.Marks@fda.hhs.gov>
Sent: Thursday, May 13, 2021 4:16 PM
To: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Cohn, Amanda (CDC/DDID/NCIRD/OD) <anc0@cdc.gov>
Cc: Gruber, Marion (FDA/CBER) <Marion.Gruber@fda.hhs.gov>; Walinsky, Sarah (FDA/CDER) <Sarah.Walinsky@fda.hhs.gov>
Subject: FW: [EXTERNAL] RE: Quick Q - vaccine coadministration

Dear Anne and Amanda,

Could we have a discussion here? We could have missed something at ACIP, but we have the following concerns:

1) We would recommend consideration be given to stating that the coadministration of live attenuated virus vaccines with COVID-19 vaccines should be avoided, if possible.

2) At the very least, there should be some mention that coadministration could possibly reduce the efficacy of either or both of the co-administered vaccines.

Thanks. If you think we are totally off base, just tell us so.

Best Regards,
Peter

From: McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>
Sent: Thursday, May 13, 2021 4:00 PM
To: Marks, Peter <Peter.Marks@fda.hhs.gov>
Subject: FW: [EXTERNAL] RE: Quick Q - vaccine coadministration

Hi Peter –

Here's the latest version.

Lorrie

From: Woodworth, Kate (CDC/DDNID/NCBDDD/DBDID) <vnt0@cdc.gov>
Sent: Thursday, May 13, 2021 3:54 PM
To: Nordlund, Kristen (CDC) <hok4@cdc.gov>; McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>; Coffin, Nicole (CDC) <ndc3@cdc.gov>
Cc: Mbaeyi, Sarah A (CDC) <vif6@cdc.gov>
Subject: [EXTERNAL] RE: Quick Q - vaccine coadministration

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Here is the latest version if helpful!

Coadministration with other vaccines

COVID-19 vaccines were previously recommended to be administered alone, with a minimum interval of 14 days before or after administration of any other vaccines. This was out of an abundance of caution and not due to any known safety or immunogenicity concerns. However, substantial data have now been collected regarding the safety of COVID-19 vaccines currently authorized by FDA for use under EUA. Although data are not available for COVID-19 vaccines administered simultaneously with other vaccines, extensive experience with non-COVID-19 vaccines has demonstrated that immunogenicity and adverse event profiles are generally similar when vaccines are administered simultaneously as when they are administered alone.

COVID-19 vaccines and other vaccines **may now be administered without regard to timing**. This includes simultaneous administration of COVID-19 vaccines and other vaccines on the same day, as well as coadministration within 14 days. It is unknown whether reactogenicity is increased with coadministration, including with other vaccines known to be more reactogenic, such as adjuvanted vaccines. When deciding whether to coadminister with COVID-19 vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable disease (e.g., during an outbreak or occupational exposures), and the reactogenicity profile of the vaccines.

If multiple vaccines are administered at a single visit, administer each injection in a different injection site. For adolescents and adults, the deltoid muscle can be used for more than one intramuscular injection.

Best practices for multiple injections include:

- Label each syringe with name and dosage (amount) of the vaccine, lot number, the initials of the preparer, and the exact beyond-use time, if applicable.
- Separate injection sites by 1 inch or more, if possible.
- **Administer COVID-19 and vaccines that may be more likely to cause a local reaction (e.g., tetanus-toxoid-containing and adjuvanted vaccines) in different limbs, if possible.**

From: Nordlund, Kristen (CDC/DDID/NCIRD/OD) <hok4@cdc.gov>

Sent: Thursday, May 13, 2021 3:49 PM

To: McNeill, Lorrie (FDA/CBER) <Lorrie.McNeill@fda.hhs.gov>; Coffin, Nicole (CDC/DDID/NCEZID/DHQP) <ndc3@cdc.gov>

Cc: Woodworth, Kate (CDC/DDNID/NCBDDD/DBDID) <vnt0@cdc.gov>; Mbaeyi, Sarah (CDC/DDID/NCIRD/OD) <vif6@cdc.gov>

Subject: RE: Quick Q - vaccine coadministration

Hi Lorrie,

We plan to updated the clinical guidance tomorrow after 1pm. Attached is the edited version of the guidance that we put up during ACIP, but I've not seen the exact language. I've cced Drs. Woodworth and Mbaeyi who are working on this in case they can share the latest version.

Thanks,
Kristen

From: McNeill, Lorrie <Lorrie.McNeill@fda.hhs.gov>

Sent: Thursday, May 13, 2021 3:43 PM

To: Nordlund, Kristen (CDC/DDID/NCIRD/OD) <hok4@cdc.gov>; Coffin, Nicole (CDC/DDID/NCEZID/DHQP) <ndc3@cdc.gov>

Subject: Quick Q - vaccine coadministration

Hi all – Dr. Marks and Dr. Woodcock participated in a stakeholder call this afternoon to discuss the authorization of the Pfizer vaccine for 12 through 15 year olds, and a question was asked about coadministration of COVID vaccine with other vaccines (meaning childhood vaccines). One of the participants said CDC was recommending that there no longer needed to be a waiting period between vaccination with COVID and other vaccines. I'm not sure he/she was completely correct. We know the issue was discussed at ACIP yesterday (I was unable to watch), but am not sure any recommendations have come out yet. Can you all let me know if there's an update?

Thanks much!

Lorrie

Lorrie H. McNeill

Director

Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
U.S. Food and Drug Administration
Tel: 240-402-8119
lorrie.mcneill@fda.hhs.gov

